https://www.biopharmawatch.com/news/OABI/omniab-raises-2026-financial-guidance BiopharmaWatch en 2026-08-17T10:06:00.000Z OmniAb Raises 2026 Financial Guidance https://www.biopharmawatch.com/news/OABI/omniab-global-collaboration-eli-lilly-ion-channel BiopharmaWatch en 2026-08-17T10:01:00.000Z OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company https://www.biopharmawatch.com/news/ZLAB/zai-lab-argenx-positive-results-efgartigimod-trial BiopharmaWatch en 2026-08-17T10:00:00.000Z Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-08-17 BiopharmaWatch en 2026-08-17T07:15:41.150Z Biotech Catalysts to Watch: Key Developments Ahead for TENX and SION https://www.biopharmawatch.com/news/ARGX/argenx-positive-results-phase-3-alkivia-trial BiopharmaWatch en 2026-08-17T05:00:00.000Z argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis https://www.biopharmawatch.com/news/MESO/mesoblast-completes-patient-treatment-phase-3-trial BiopharmaWatch en 2026-08-17T00:35:00.000Z Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain